immunotherapy

From the Field

Anticipated Cost Savings with Alternate Dosing Schema of Nivolumab/Ipilimumab for the Treatment of Metastatic Melanoma

08/20/2021

Allison Kupsh, PharmD

Laura Alwan, PharmD

Eve Segal, PharmD

Kate Trieselmann, PharmD

Evan Hall, MD

Allison Kupsh, PharmD, and colleagues found that the anticipated cost of NIVO3+IPI1 for the treatment of metastatic melanoma may be lower compared when compared with NIVO1+IPI3, amounting to over $1,000,000 in total savings.

Allison Kupsh, PharmD, and...

08/20/2021

Journal of Clinical Pathways

Research in Review

Immunotherapy Better Than Standard of Care for Type of DLBCL

08/03/2017

JCP Editors

Single-agent immunotherapy in patients with a subtype of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) provides more clinical benefit than conventional therapy, according to research published in...

...

08/03/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Diminishes Regulatory T-Cells, Improves Outcomes in AML

07/20/2017

JCP Editors

Immunotherapy after complete remission in acute myeloid leukemia (AML) is associated with decreasing levels of regulatory T-cells, which leads to favorable clinical outcomes, according to research published in Cancer...

...

07/20/2017

Journal of Clinical Pathways

Research in Review

Altered B-Cell Composition May Impact Immunotherapy Effectiveness in AML

07/13/2017

JCP Editors

Initial chemotherapy often alters B-cell composition and immunity in patients with acute myeloid leukemia (AML), which may have implications for the success of further immunotherapy, according to research published...

...

07/13/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Shows Promise in Rare Type of Lymphoma

07/11/2017

JCP Editors

A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...

A...

07/11/2017

Journal of Clinical Pathways

Research in Review

PD-1 Inhibitor Improves Response Rates, Survival Times in Certain Patients With NSCLC

06/23/2017

JCP Editors

A programmed death 1 (PD-1) inhibitor is associated with similar efficacy to chemotherapy in patients with non-small cell lung cancer (NSCLC), but improves response rates and survival times in subgroups of patients,...

A...

06/23/2017

Journal of Clinical Pathways

Research in Review

Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes

06/16/2017

JCP Editors

A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...

A...

06/16/2017

Journal of Clinical Pathways

Research in Review

PD-L2 Expression May Indicate Response to Immunotherapy in Head and Neck Cancer

06/15/2017

JCP Editors

A recent study suggests that immunotherapies targeting both PD-L1 and PD-L2 may enhance response rates for patients with head and neck squamous cell carcinoma (HNSCC), published in Clinical Cancer Research (published...

A...

06/15/2017

Journal of Clinical Pathways

Research in Review

Immunotherapy Improves Standard of Care for Multiple Myeloma

06/08/2017

JCP Editors

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd,...

Adding...

06/08/2017

Journal of Clinical Pathways

Research in Review

PD-L1 Testing Uncommon Among NSCLC Patients on Immunotherapy

06/03/2017

JCP Editors

Few patients treated with immunotherapy for metastatic non–small cell lung cancer (NSCLC) at United States community practices receive appropriate programmed death-ligand 1 (PD-L1) expression testing, according to...

Few...

06/03/2017

Journal of Clinical Pathways